Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2015, Article ID 391848, 4 pages
http://dx.doi.org/10.1155/2015/391848
Research Article

An International Survey of Health Care Providers Involved in the Management of Cancer Patients Exposed to Cardiotoxic Therapy

1The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, ON, Canada K1H 8L6
2Vanderbilt Heart and Vascular Institute, Nashville, TN 37232, USA
3The Ottawa Hospital Division of Cardiology, University of Ottawa, Ottawa, ON, Canada K1H 8L6

Received 18 October 2014; Accepted 29 December 2014

Academic Editor: Bruno Vincenzi

Copyright © 2015 Jeffrey Sulpher et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Age-standardized mortality rates by selected causes, by sex Ottawa: Statistics Canada, 2014, http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/health30a-eng.htm.
  2. G. Curigliano, D. Cardinale, T. Suter et al., “Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines,” Annals of Oncology, vol. 23, supplement 7, pp. vii155–vii166, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. I. N. Daher, T. R. Daigle, N. Bhatia, and J.-B. Durand, “The prevention of cardiovascular disease in cancer survivors,” Texas Heart Institute Journal, vol. 39, no. 2, pp. 190–198, 2012. View at Google Scholar · View at Scopus
  4. D. A. Dillman, Mail and Internet Surveys: The Tailored Design Method, Wiley and Sons, 1999.
  5. M. G. Khouri, P. S. Douglas, J. R. Mackey et al., “Cancer therapy-induced cardiac toxicity in early breast cancer addressing the unresolved issues,” Circulation, vol. 126, no. 23, pp. 2749–2763, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. J. C. Plana, M. Galderisi, A. Barac et al., “Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging,” European Heart Journal—Cardiovascular Imaging, vol. 15, no. 10, pp. 1063–1093, 2014. View at Google Scholar
  7. M. S. Ewer, M. T. Vooletich, J.-B. Durand et al., “Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment,” Journal of Clinical Oncology, vol. 23, no. 31, pp. 7820–7826, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Albini, G. Pennesi, F. Donatelli, R. Cammarota, S. de Flora, and D. M. Noonan, “Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention,” Journal of the National Cancer Institute, vol. 102, no. 1, pp. 14–25, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. T. M. Suter and M. S. Ewer, “Cancer drugs and the heart: importance and management,” European Heart Journal, vol. 34, no. 15, pp. 1102–1111, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. E. T. H. Yeh, A. T. Tong, D. J. Lenihan et al., “Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management,” Circulation, vol. 109, no. 25, pp. 3122–3131, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. C. Thorpe, B. Ryan, S. L. McLean et al., “How to obtain excellent response rates when surveying physicians,” Family Practice, vol. 26, no. 1, pp. 65–68, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Barclay, C. Todd, I. Finlay, G. Grande, and P. Wyatt, “Not another questionnaire! Maximizing the response rate, predicting non-response and assessing non-response bias in postal questionnaire studies of GPs,” Family Practice, vol. 19, no. 1, pp. 105–111, 2002. View at Publisher · View at Google Scholar · View at Scopus